Overall rank by patents
#35,746
Across all tracked assignees
USPTO 2015–2025 USPTO PatentsView US Corporation
Horizon Therapeutics USA, Inc.
USPTO PatentsView assignee record - 7 granted patents across 5 technology areas, active 2022–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS).
7
Total patents granted
5
CPC technology areas
14.0
Avg claims per patent
-
5-year filing velocity
The verdict
Horizon holds 7 US patents across 5 technology areas, rank #35,746 of 50,000 tracked assignees.
- #35,746
- of 50,000 US assignees by volume
- Top 28%
- by Innovation Score (43.5/100)
- 14.0
- avg claims per patent
Portfolio overview
Horizon Therapeutics USA, Inc. has been granted 7 US utility patents between 2022 and 2025, placing Horizon Therapeutics USA, Inc. at rank #35,746 across all assignees tracked by PlainPatent. This portfolio spans 5 distinct Cooperative Patent Classification (CPC) subclasses, averaging 14.0 claims per patent with primary concentration in A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS). As a US Corporation, Horizon Therapeutics USA, Inc. is one of the more focused assignees in the PatentsView dataset. By volume, Horizon sits between Hiveio Inc. (7 patents, rank #35,742) and Hotberry, Llc (7 patents, rank #35,750) - the closest US assignees by grant volume. The composite Innovation Score of 43.5/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Historical data spans 2022 through 2025, with 7 total grants over that period. Velocity comparisons require five years of historical filings to calibrate. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Horizon Therapeutics USA, Inc.'s 14.0 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while concentration in 5 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Horizon Therapeutics USA, Inc. against peers pursuing similar technology classes.
Who files at Horizon's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- Hiveio
HiveIO Inc.
7 patents
- Hobie Cat IP
Hobie Cat IP, LLC
7 patents
- Hola Networks
Hola Networks Ltd.
7 patents
- Hopgrade
Hopgrade, Inc.
7 patents
- Horning Manufactu…
Horning Manufacturing, LLC
7 patents
- Horst Siedle & KG
Horst Siedle GmbH & Co. KG
7 patents
- Hotstart
HotStart, Inc.
7 patents
- Hotberry
Hotberry, LLC
7 patents
- Horizon Therapeut… ◀
Horizon Therapeutics USA, Inc.
7 patents
What this shows Horizon holds 7 patents at rank #35,746, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Companies ranked near Horizon
By rank, the assignees closest to #35,746 in granted patent volume.
- Hiveio Inc. #35,742 · 7 patents
- Hobie Cat IP, Llc #35,743 · 7 patents
- Hola Networks Ltd. #35,744 · 7 patents
- Hopgrade, Inc. #35,745 · 7 patents
- Horning Manufacturing, Llc #35,747 · 7 patents
- Horst Siedle Gmbh & Co. KG #35,748 · 7 patents
- Hotstart, Inc. #35,749 · 7 patents
- Hotberry, Llc #35,750 · 7 patents
Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)
Other assignees with the most granted patents in Horizon's primary technology class.
- The Regents Of The University Of California 1,387 in class
- Novartis Ag 1,071 in class
- Merck Sharp & Dohme Llc 889 in class
- Bristol-myers Squibb Company 879 in class
- Genentech, Inc. 789 in class
- The Board Of Regents Of The University Of Texas System 744 in class
- Hoffmann-la Roche Inc. 722 in class
- The United States Of America, As Represented By The Secretary, Department Of Health And Human Services 721 in class
Horizon's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
43 Top 28% higher than 72% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2022–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2022 | 1 | 14.3% |
| 2023 | 3 | 42.9% |
| 2024 | 2 | 28.6% |
| 2025 | 1 | 14.3% |
Which technologies does Horizon Therapeutics USA, Inc. patent most?
Top 5 of 5 technology areas
Patent Moat Analysis
Portfolio Volume Light
Tech Breadth Focused
Claim Depth Standard
Frequently Asked Questions
How many patents does Horizon Therapeutics USA, Inc. hold?
Horizon Therapeutics USA, Inc. holds 7 US granted patents filed between 2022 and 2025, spanning 5 technology areas.
What is Horizon Therapeutics USA, Inc.'s Innovation Score?
Horizon Therapeutics USA, Inc. has an Innovation Score of 43.5 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does Horizon Therapeutics USA, Inc. focus on?
Horizon Therapeutics USA, Inc.'s top technology area is A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS) with 7 patents. The company has filed patents in 5 CPC subclasses total.
Is Horizon Therapeutics USA, Inc.'s patent filing rate increasing or decreasing?
Insufficient historical data is available to calculate a velocity trend for Horizon Therapeutics USA, Inc..
What does claim depth mean for Horizon Therapeutics USA, Inc.'s patents?
Horizon Therapeutics USA, Inc.'s patents average 14.0 claims each. This falls within the standard range, providing solid legal coverage.
How is the Horizon Therapeutics USA, Inc. patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.
How to use this portfolio
Horizon's 7 grants land it in the top 28% by Innovation Score, but volume alone doesn't tell you where the strength sits.
- Read that count against the largest US assignees before treating it as dominance - Horizon ranks #35,746 of 50,000. Top 50 holders
- Most of this portfolio concentrates in A61P - see who else leads that technology area. A61P leaders
- Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.